Eculizumab and ravulizumab are anti-C5 monoclonal antibodies that inhibit the terminal complement system, reducing hemolysis, anaemia, occurrence of thrombosis and PNH-related mortality. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.